GlaxoSmithKline ($GSK) has reached out to the storied Cold Spring Harbor Laboratory to collaborate on a potential treatment for Type 2 diabetes and obesity, inking a multiyear R&D deal. Under the agreement, the two will work together on small-molecule candidates that block the phosphatase PTP1B in hopes of making the body more receptive to insulin and battling diabetes and obesity. The collaboration, run through GSK's Discovery Partnership with Academia program, is designed to accelerate the company's in-house projects in metabolic disease. More